Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
Status:
Not yet recruiting
Trial end date:
2025-12-15
Target enrollment:
Participant gender:
Summary
This Phase 2 study examines the safety, tolerability, and preliminary efficacy of
pimavanserin in individuals with Autism Spectrum Disorder. Male or female participants aged
16 to 40 years of age will be randomized to receive single doses of either placebo or
pimavanserin in this randomized, placebo-controlled, cross-over designed study, followed by
open label extension.
Phase:
Phase 2
Details
Lead Sponsor:
New York State Psychiatric Institute
Collaborators:
ACADIA Pharmaceuticals Inc. Research Foundation for Mental Hygiene, Inc. University of Kansas Medical Center Weill Medical College of Cornell University